

## References

I-41

1. Clinical Pharmacology™ 2024. Tampa FL: Gold Standard, Inc. Carfilzomib.
2. Bhutani D, Zonder BD. Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma. *Blood and Lymphatic Cancer: Targets and Therapy*.2017; 53-60.
3. Boccia RV, Bessudo A, Agajanian R, et al. Multicenter, Open-Label, Phase 1b Study of carfilzomib, cyclophosphamide, and dexamethasone in newly diagnosed multiple myeloma patients *Clin Lymphoma, Myeloma & Leuk*. 2017; 433-437.
4. Jakubowiak AJ, DeCara JM, Mezzi K. Cardiovascular events during carfilzomib therapy for relapsed myeloma: practical management aspects from two case studies. *Hematology*. 2017; 22(10):585-91.
5. Kyprolis (Carfilzomib), for injection [package insert]. Onyx Pharmaceuticals, Inc. Thousand Oaks, CA. Revised 06/2022.
6. Shah, C., Bishnoi, R., Wang, Y., et. al. Efficacy and safety of carfilzomib in relapsed and/or refractory multiple myeloma: Systematic review and meta-analysis of 14 trials. *Oncotarget*,2018;9(34):23704-23717.
7. Chen, R., Chen, B., Zhang, X, et.al. Efficacy of carfilzomib in the treatment of relapsed and (or) refractory multiple myeloma: a meta-analysis of data from clinical trials. *Discovery Medicine*. 2016;22(121):189-199.
8. Chaudhry M, Steiner R, Claussen C, et al. Carfilzomib-based combination regimens are highly effective frontline therapies for multiple myeloma and Waldenström's macroglobulinemia. *Leukemia & Lymphoma*. 2019;60(4):964-970.
9. Micromedex DrugDex Compendium®. 2024. Carfilzomib (Kyprolis).
10. National Comprehensive Cancer Network (NCCN). Carfilzomib. NCCN Drugs and Biologics Compendium®. 2024.
11. Carfilzomib In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated April 6, 2016.